SissonJC, FreitasJ, McDougallIR, DauerLT, HurleyJR, BrierleyJD, EdinboroCH, RosenthalD, ThomasMJ, WexlerJA, AsamoahE, AvramAM, MilasM, GreenleeC. The American Thyroid Association Taskforce on Radiation Safety. 2011. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations by the American Thyroid Association. Thyroid, 21:335–346.
2.
MathieuI, CaussinJ, SmeestersP, WambersieA, BeckersC. 1999. Recommended restrictions after 131I therapy: measured doses in family members. Health Phys, 76:129–126.
3.
ReinhardtMJ, BrinkI, JoeAY, von MallekD, EzziddinS, PalmedoH, KrauseTM. 2002. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment volume on clinical outcome. Eur J Nucl Med, 29:1118–1124.
4.
ClercJ, IzembartM, DagoussetF, JaisJ-P, HeshmanHM, ChevalierA, LegerAF, BarritaultL. 1993. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med, 34:387–393.
5.
BergGEB, MichanekAMK, HolmbergECV, FinkM. 1996. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med, 37:228–232.
6.
BarringtonSF, O'DohertyMJ, KettleAG, ThomsonWH, MountfordPJ, BurrellDN, FarrellRJ, BatchelorS, SeedP, HardingLK. 1999. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med, 26:686–692.
